Skip to content
VRTX Vertex Pharmaceuticals Inc NASDAQ
329.99 USD -0.79% -2.64
OPEN 328.99
DAY RANGE 331.78 - 325.82
52 WEEK RANGE 354.46 - 243.17
Interactive Brokers Logotype

Buy VRTX stocks now with Interactive Brokers – the most advanced investment platform

Valuations metrics

Market capitalization 85B
Enterprise value 75.4B
Trailing pe 26.526527
Forward pe 21.940825
Peg ratio 21.940825
Price to sales ttm 9.229972
Price to book mrq 5.8878417
Enterprise to revenue 8.185
Enterprise to ebitda 16.318


Fiscal year ends 2022-12-31
Most recent quarter 2023-03-31
Profit margin 0.35401002
Operating margin 0.48514
Return on assets ttm 0.16804
Return on equity ttm 0.25728
Income statement
Revenue ttm 9.2B
Revenue per share ttm 35.874
Quarterly revenue growth 0.132
Gross profit ttm 5.3B
Ebitda 4.6B
Net income to common ttm 3.3B
Diluted eps ttm 12.44
Quarterly earnings growth yoy -0.082
Balance sheet
Total cash mrq 10.4B
Total cash per share mrq 40.435
Total debt mrq 789.2M
Total debt to equity mrq 5.468
Current ratio mrq 4.284
Book value per share mrq 56.046
Cash flow
Operating cash flow ttm 4.1B
Levered free cash flow ttm 3.6B

Stock statistics

Shares outstanding 257.6M
Float shares 256.9M
Avg 10 volume 1.1M
Avg 30 volume 1.1M
Shares short 3.2M
Short ratio 2.94
Short percent of shares outstanding 0.0125
Percent held by insiders 0.00159
Percent held by institutions 0.95879996

Stock price summary

Fifty two week low 243.17
Fifty two week high 354.46
Fifty two week change 18.588
Beta 0.490499
Day 50 ma 329.1588
Day 200 ma 306.3193

Dividends and splits

Last split factor 2-for-1 split
Last split date 2000-08-24

Vertex Pharmaceuticals (VRTX) company profile

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a biotechnology company. The company discovers, develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The firm solutions treat cystic fibrosis, infectious diseases, and autoimmune diseases.